Skip to main content
Top
Published in: Diabetologia 6/2006

01-06-2006 | Short Communication

Increased prevalence of Down’s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study

Authors: R. Bergholdt, S. Eising, J. Nerup, F. Pociot

Published in: Diabetologia | Issue 6/2006

Login to get access

Abstract

Aims/hypothesis

In patients with Down’s syndrome, dogma has long held that the prevalence of diabetes is increased. The aim of the present study was to determine the actual prevalence of Down’s syndrome among type 1 diabetic patients.

Subjects, materials and methods

The background population included all children born in Denmark between 1981 and 2000. Registry-validated and clinical data on type 1 diabetes and Down’s syndrome diagnoses were obtained from the National Disease Register and Danish Cytogenetic Central Register, respectively.

Results

The prevalence of Down’s syndrome in the background population was 0.09%, whereas we identified a prevalence of Down’s syndrome in type 1 diabetes patients of 0.38% (95% CI 0.17–0.75), corresponding to a 4.2-fold increased prevalence compared with the background population (p=7.3×10−5).

Conclusions/interpretation

To the best of our knowledge this is the first population-based study addressing the prevalence of Down’s syndrome among verified type 1 diabetes patients. A more than fourfold increased prevalence of Down’s syndrome among type 1 diabetes patients supports the notion that genes on chromosome 21 may confer risk for type 1 diabetes, probably also in the general population.
Literature
1.
go back to reference Shield JPH, Wadsworth EJK, Hassold TJ, Judis LA, Jacobs PA (1999) Is disomic homozygosity at the APECED locus the cause of increased autoimmunity in Down’s syndrome? Arch Dis Child 81:147–150PubMed Shield JPH, Wadsworth EJK, Hassold TJ, Judis LA, Jacobs PA (1999) Is disomic homozygosity at the APECED locus the cause of increased autoimmunity in Down’s syndrome? Arch Dis Child 81:147–150PubMed
2.
go back to reference Pickup J, Williams G (1991) Textbook of diabetes, 1st ed. Blackwell, Malden, USA Pickup J, Williams G (1991) Textbook of diabetes, 1st ed. Blackwell, Malden, USA
3.
go back to reference Milunsky A, Neurath PW (1968) Diabetes mellitus in Down’s syndrome. Arch Environ Health 17:372–376PubMed Milunsky A, Neurath PW (1968) Diabetes mellitus in Down’s syndrome. Arch Environ Health 17:372–376PubMed
4.
go back to reference Jeremiah DE, Leyshon GE, Rose T, Francis HW, Elliott RW (1973) Down’s syndrome and diabetes. Psychol Med 3:455–457PubMed Jeremiah DE, Leyshon GE, Rose T, Francis HW, Elliott RW (1973) Down’s syndrome and diabetes. Psychol Med 3:455–457PubMed
5.
go back to reference Burch PR, Milunsky A (1969) Early-onset diabetes mellitus in the general and Down’s syndrome populations. Genetics, aetiology, and pathogenesis. Lancet 1:554–558PubMedCrossRef Burch PR, Milunsky A (1969) Early-onset diabetes mellitus in the general and Down’s syndrome populations. Genetics, aetiology, and pathogenesis. Lancet 1:554–558PubMedCrossRef
6.
go back to reference Sjoroos M, Iitia A, Ilonen J, Reijonen H, Lovgren T (1995) Triple-label hybridization assay for type-1 diabetes-related HLA alleles. Biotechniques 18:870–877PubMed Sjoroos M, Iitia A, Ilonen J, Reijonen H, Lovgren T (1995) Triple-label hybridization assay for type-1 diabetes-related HLA alleles. Biotechniques 18:870–877PubMed
7.
go back to reference Lambert A, Gillespie K, Thomson G et al (2004) Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89:4037–4043PubMedCrossRef Lambert A, Gillespie K, Thomson G et al (2004) Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89:4037–4043PubMedCrossRef
8.
go back to reference Van-Goor JC, Massa GG, Hirasing R (1997) Increased incidence and prevalence of diabetes mellitus in Down’s syndrome. Arch Dis Child 77:186PubMed Van-Goor JC, Massa GG, Hirasing R (1997) Increased incidence and prevalence of diabetes mellitus in Down’s syndrome. Arch Dis Child 77:186PubMed
9.
go back to reference Anwar A, Walker J, Frier B (1998) Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med 15:160–163PubMedCrossRef Anwar A, Walker J, Frier B (1998) Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med 15:160–163PubMedCrossRef
10.
go back to reference Ivarsson S, Ericsson U, Gustafsson J, Forslund M, Vegfors P, Anneren G (1997) The impact of thyroid autoimmunity in children and adolescents with Down’s syndrome. Acta Paediatr 86:1065–1067PubMedCrossRef Ivarsson S, Ericsson U, Gustafsson J, Forslund M, Vegfors P, Anneren G (1997) The impact of thyroid autoimmunity in children and adolescents with Down’s syndrome. Acta Paediatr 86:1065–1067PubMedCrossRef
11.
go back to reference Agardh D, Nilsson A, Carlsson A, Kockum I, Lernmark A, Ivarsson S (2002) Tissue transglutaminase autoantibodies and human leucocyte antigen in Down’s syndrome patients with coeliac disease. Acta Paediatr 91:34–38PubMedCrossRef Agardh D, Nilsson A, Carlsson A, Kockum I, Lernmark A, Ivarsson S (2002) Tissue transglutaminase autoantibodies and human leucocyte antigen in Down’s syndrome patients with coeliac disease. Acta Paediatr 91:34–38PubMedCrossRef
12.
go back to reference Serrano-Rios M, Mato J, Oya M, Larrodera L, Hawkins F, Escobar F (1973) Failure to find Ig-G insulin antibodies in Down's syndrome. Horm Metab Res 5:57–58PubMedCrossRef Serrano-Rios M, Mato J, Oya M, Larrodera L, Hawkins F, Escobar F (1973) Failure to find Ig-G insulin antibodies in Down's syndrome. Horm Metab Res 5:57–58PubMedCrossRef
Metadata
Title
Increased prevalence of Down’s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study
Authors
R. Bergholdt
S. Eising
J. Nerup
F. Pociot
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0231-6

Other articles of this Issue 6/2006

Diabetologia 6/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.